Jennifer Bernard, MD
Endocrinology, Diabetes & Metabolism · Lakewood, CONPI 1275706285
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.2% of the total across 64 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $443 and has fallen 56.8% since, to $192 in 2025.
Across 64 payments — averaging $22.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$198
- Medtronic$159
- Tandem Diabetes Care, Inc.$141
- Radius Health, Inc.$95
- AstraZeneca$87
- Bristol Myers Squibb$81
- plus $700 from 21 others
What the payments were for
- Food & beverage$1,40696%
- Education$554%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 4 | $198 |
| Medtronic(2 entities) | 6 | $159 |
| Tandem Diabetes Care, Inc. | 6 | $141 |
| Radius Health, Inc. | 3 | $95 |
| AstraZeneca(2 entities) | 4 | $87 |
| Bristol Myers Squibb | 5 | $81 |
| Amgen | 4 | $77 |
| Sanofi-aventis U.S. LLC | 3 | $74 |
| Amneal Pharmaceuticals LLC | 4 | $58 |
| Lilly USA, LLC | 4 | $54 |
| Sequel Med Tech, LLC | 3 | $53 |
| Mannkind Corporation | 1 | $43 |
| BETA Bionics, Inc. | 2 | $38 |
| Novo Nordisk | 2 | $37 |
| Antares Pharma, Inc. | 1 | $31 |
| Johnson & Johnson | 1 | $26 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Shire North American Group Inc | 1 | $23 |
| Abbott | 1 | $22 |
| BD | 1 | $21 |
| Lifescan, Inc. | 1 | $19 |
| Novartis | 1 | $19 |
| Dexcom, Inc. | 1 | $18 |
| Corcept Therapeutics | 1 | $18 |
| Clarus Therapeutics Inc. | 1 | $18 |
| AbbVie | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$156
How this compares
$1,461 in reported general payments places this provider in the 55th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
See all endocrinology, diabetes & metabolism providers in Colorado →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TymlosAbaloparatide | 19 | $51,866 |
| MounjaroTirzepatide | 33 | $39,278 |
| TrulicityDulaglutide | 32 | $37,796 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 25 | $35,572 |
| Teriparatide | 11 | $26,872 |
| OzempicSemaglutide | 21 | $21,175 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 11 | $9,275 |
| SynthroidLevothyroxine Sodium | 90 | $7,342 |
| TirosintLevothyroxine Sodium | 15 | $5,535 |
| Levothyroxine Sodium | 365 | $3,573 |
| UnithroidLevothyroxine Sodium | 14 | $2,241 |
| Hydrocortisone | 22 | $1,586 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 16 | $1,513 |
| Liothyronine Sodium | 28 | $1,001 |
| Calcitriol | 32 | $748 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $54 | $77,07465 claims |
| Radius Health, Inc.Tymlos | $95 | $51,86619 claims |
| Novo NordiskOzempic | $37 | $21,17521 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $74 | $9,27511 claims |
| AbbVieSynthroid | $16 | $7,34290 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $58 | $5,814379 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
Other endocrinology, diabetes & metabolism in Lakewood
- Kevin TongLakewood$3K
- Alexandra ReiherLakewood$1K
- Rachana ThapaLakewood$967
- Leigh PerreaultBoulder$1.7M
- Satish GargAurora$347K
- Viralkumar ShahAurora$256K
- Neda RasouliAurora$188K
- Michelle CassaraArvada$141K
- Halis AkturkAurora$109K
- Irinel StanciuArvada$104K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.